Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BHFAN vs MET: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MET Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

MET Overall Winner 6-Pillar Tally: BHFAN 1 – 5 MET Matrix Metrics: BHFAN 4 – 6 MET

As of Nov 20, 2026, MetLife, Inc. (MET) is the stronger overall head-to-head candidate over Brighthouse Financial, Inc. Depositary shares, each representing a 1/1,000th interest in a share of 5.375% Non-Cumulative Preferred Stock, Series C (BHFAN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BHFAN carries a Unified Composite Score of 33.7/100 (SELL) at $9.18 (N/M Forward P/E, 18.4% operating margin), whereas MET carries 44.6/100 (HOLD) at $95.67 (8.6x Forward P/E, 8.5% operating margin).

  • Technical & Structure Timing Caution: BHFAN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.9); meanwhile MET trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHFAN vs MET
BHFAN NASDAQ
Brighthouse Financial, Inc. Depositary shares, each representing a 1/1,000th interest in a share of 5.375% Non-Cumulative Preferred Stock, Series C
Life Insurance
$9.18
-0.65% 1D
Market Cap N/A
TTM Revenue $5.81B
Forward P/E N/M
Beta / 30D Vol 0.36β · 16% Vol
Unified Composite Score
33.7 / 100 SELL
Tech 18.0 Fund 37.0 Flow 50.0 Mom 49.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.0%), weak momentum, RSI 18
RSI-14: 17.9 · SMA20: $10.09 · SMA50: $10.65
MET NYSE Head-to-Head Winner
MetLife, Inc.
Life Insurance
$95.67
-1.98% 1D
Market Cap $61.3B
TTM Revenue $82.6B
Forward P/E 8.6x
Beta / 30D Vol 0.55β · 28% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 47.0 Fund 51.0 Flow 52.0 Mom 56.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 37.5 · SMA20: $100.53 · SMA50: $99.01

6-Pillar Scorecard Institutional Category Breakdown (BHFAN 1 – 5 MET)

Columns: Metric · BHFAN · MET
1. Valuation Multiples MET
Forward P/E N/M 8.6x
Trailing P/E 0.7x 12.8x
PEG Ratio N/M 0.53x
EV / Revenue N/M 0.8x
2. Growth & Scale MET
Revenue Growth (YoY) -52.7% +18.2%
Earnings Growth (YoY) -34.0% +200.8%
TTM Revenue (USD) $5.81B $82.6B
Market Cap N/A $61.3B
3. Profitability & Quality BHFAN
Gross Margin 16.5% 25.6%
Operating Margin 18.4% 8.5%
Net Profit Margin 11.7% 6.2%
Return on Equity (ROE) 11.9% 19.9%
4. Balance Sheet & Cash Flow MET
Cash Generation (TTM) N/A $14.0B
Cash Flow Margin N/A 16.9%
Net Cash / Leverage $87.13 Book/Sh · 11.9% ROE $1.89B Net Debt (0.98x D/E)
Dividend Yield 14.25% 2.32%
5. Options & Positioning MET
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 30.4% (13th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MET
OpEx & R&D Intensity N/A 17.1% of Rev ($14.1B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Insurance - Life Operator Insurance - Life Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHFAN (4) vs MET (6)
Institutional Metric BHFAN MET Criterion Row Edge
Market Capitalization
Scale
N/A $61.3B Larger Scale MET
Trailing P/E Ratio
Valuation
0.7x 12.8x Lower Multiple BHFAN
Forward P/E Ratio
Valuation
N/M 8.6x Lower Multiple MET
Revenue Growth (YoY)
Growth
-52.7% +18.2% Higher Growth MET
Operating Margin (TTM)
Profitability
18.4% 8.5% Higher Margin BHFAN
Net Profit Margin
Profitability
11.7% 6.2% Higher Margin BHFAN
Return on Equity (ROE)
Capital Efficiency
11.9% 19.9% Higher ROE MET
52-Week Range Position
Momentum
0% ($9–$14) 72% ($67–$107) Stronger Trend MET
Beta / 30D Volatility
Risk Regime
0.36β · 16% Vol 0.55β · 28% Vol Lower Realized Risk BHFAN
Unified Institutional Score
Composite Signal
33.7 / 100 (SELL) 44.6 / 100 (HOLD) Higher Composite MET
Trailing 12M Revenue (USD)
Operating Scale
$5.81B $82.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.5% 25.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.53x PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($87.13 Book/Sh · 11.9% ROE) $14.0B ($1.89B Net Debt (0.98x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MET +4.61 pp
BHFAN: -12.24% · MET: -7.63%
3M Horizon MET +20.84 pp
BHFAN: -21.4% · MET: -0.56%
6M Horizon MET +40.66 pp
BHFAN: -26.85% · MET: +13.81%
1Y Horizon MET +56.97 pp
BHFAN: -29.0% · MET: +27.97%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHFAN vs MET. Trailing 12-month operating profitability (BHFAN 18.4% vs MET 8.5%) and valuation multiples (BHFAN N/M vs MET 8.6x Forward P/E) are benchmarked directly in Pillar 4 below.

BHFAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.81B
Gross Margin16.5%
Op. Margin18.4%
ROE / Fwd P/E11.9% · N/M
MET ADR TTM Benchmark FX-Normalized USD
TTM Revenue$82.6B
Gross Margin25.6%
Op. Margin8.5%
ROE / Fwd P/E19.9% · 8.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHFAN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHFAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MET UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.4%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MET Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $101.45 · IV 25.8%

MET Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($10,145)

Compare $10,145 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 25.8% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $97.5 / $90 Bull Put Spread

Sell 1x $97.5P · Buy 1x $90P · 31d

Net Entry $87 Credit
Max Credit / Yield +$87 (+13.1% RoM)
Max Risk / Buffer -4.8% Cushion ($663 Mgn)
5d Edge & Liquidity 73% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $105 / $97.5 Bear Put Spread

Buy 1x $105P · Sell 1x $97.5P · 31d

Net Entry $268 Debit
T+5d @ -5% Drop +$250 (+93%)
Max Risk / Buffer $268 Capped
5d Edge & Liquidity 1.2x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHFAN Moat Profile Scale & Operating Efficiency Moat
Insurance - Life Operator
Competes within the Insurance - Life value chain with N/A market capitalization and 18.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MET Moat Profile Scale & Operating Efficiency Moat
Insurance - Life Operator
Competes within the Insurance - Life value chain with $61.3B market capitalization and 8.5% operating margin.
OpEx & R&D Reinvestment 17.1% of Rev ($14.1B)
90D Engineering Disclosures 0 Published

Investor FAQ BHFAN vs MET Key Questions & Quantitative Answers

As of Nov 20, 2026, MetLife, Inc. (MET) is the stronger overall head-to-head candidate over Brighthouse Financial, Inc. Depositary shares, each representing a 1/1,000th interest in a share of 5.375% Non-Cumulative Preferred Stock, Series C (BHFAN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BHFAN carries a Unified Composite Score of 33.7/100 (SELL) at $9.18 (N/M Forward P/E, 18.4% operating margin), whereas MET carries 44.6/100 (HOLD) at $95.67 (8.6x Forward P/E, 8.5% operating margin). Technical & Structure Timing Caution: BHFAN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.9); meanwhile MET trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MET leads the Growth & Scale pillar: BHFAN posts -52.7% YoY revenue growth and -34.0% YoY earnings growth on $5.81B TTM revenue (16.5% gross margin, 18.4% operating margin), compared with MET at +18.2% YoY revenue growth and +200.8% YoY earnings growth on $82.6B TTM revenue (25.6% gross margin, 8.5% operating margin). On trailing 12-month operating scale, BHFAN generates $5.81B in USD-normalized revenue versus $82.6B for MET. In operating R&D and SG&A reinvestment, BHFAN deploys N/A (0 90-day corporate R&D disclosures) versus 17.1% of Rev ($14.1B) (0 disclosures) for MET.

MET screens cheaper on headline valuation multiples. BHFAN trades at N/M Forward P/E, 0.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MET trades at 8.6x Forward P/E, 12.8x Trailing P/E, 0.53x PEG, and 0.8x EV/Revenue (16.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHFAN (11.9% ROE) versus MET (19.9% ROE) capital efficiency.

In options market volatility and institutional positioning, BHFAN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.36β · 16% Vol realized risk). By comparison, MET carries 30.4% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.55β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Brighthouse Financial, Inc. Depositary shares, each representing a 1/1,000th interest in a share of 5.375% Non-Cumulative Preferred Stock, Series C (BHFAN) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.